A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme

This publication has 33 references indexed in Scilit:

• Structural and functional specificities of PDGF‐C and PDGF‐D, the novel members of the platelet‐derived growth factors family
  The FEBS Journal, 2005
• Emerging Data on IMiDs in the Treatment of Myelodysplastic Syndromes (MDS)
  Seminars in Oncology, 2005
• Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
  New England Journal of Medicine, 2005
• Thalidomide as a novel therapeutic agent: new uses for an old product
  Drug Discovery Today, 2005
• Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas
  Journal of Clinical Oncology, 2003
• Genetic modulation of hypoxia induced gene expression and angiogenesis relevance to brain tumors
  Frontiers in Bioscience-Landmark, 2003
• Future directions for temozolomide therapy
  Seminars in Oncology, 2001
• A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
  British Journal of Cancer, 2000
• Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas
  Journal of Neuro-Oncology, 1994
• Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.
  The Journal of Experimental Medicine, 1993